Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
- Xenitra (ASX:XEN) jumped 60.00% after securing a three-year procurement agreement worth at least A$12 million with Kangsheng.
- Artrya (ASX:AYA) fell 28.55% despite two US health systems already generating revenue from its Salix platform.
- InteliCare (ASX:ICR) rose 27.78% after reporting its first positive cash-flow quarter since listing.
- 4DMedical (ASX:4DX) gained 16.72% after signing SimonMed Imaging to deploy its lung imaging system across more than 170 US centres.
- Capital raises and stronger cash reserves featured across biotech and medical technology, including PYC Therapeutics (ASX:PYC), Echo IQ (ASX:EIQ) and Vitrafy (ASX:VFY).
The biggest moves came from Xenitra (ASX:XEN), Artrya (ASX:AYA) and InteliCare (ASX:ICR). Xenitra surged 60.00% after signing a three-year, A$12 million minimum procurement deal with Chinese distributor Kangsheng. Artrya dropped 28.55%, even though two US health systems now generate revenue from its Salix heart imaging platform. InteliCare climbed 27.78% after producing A$384,000 in positive cash flow during the June quarter.
Artrya’s fall continued after the stock reopened at $5.81 and moved 30.64% lower from that level. The briefing points to no new setback in the business. The price move may reflect selling after earlier gains, or concern about the timing of expected US regulatory clearance. The company says its FDA submission for the Salix Coronary Flow module is near completion.
More products reaching US patients
US expansion remained a central theme. 4DMedical (ASX:4DX) gained 16.72% after SimonMed Imaging agreed to use its CT:VQ lung imaging system across more than 170 outpatient centres. Revenue rose 23% to $7.2 million, while scan volumes grew 43%. Imricor Medical Systems (ASX:IMR) began US sales with Rady Children’s Hospital, San Diego as its first customer. Its shares fell 3.12% for the week and then moved 7.92% lower after reopening at $2.02. The company must now turn early hospital interest into repeat system sales.
Cyclopharm (ASX:CYC) gained 4.46% after new US lung imaging guidance named Technegas as the preferred ventilation agent. The guidance also supports three-dimensional scans and lower radiation exposure. Saluda Medical (ASX:SLD) rose 11.25% after FDA approval for its CAP24 paddle lead opened access to more US spinal surgery procedures. FY26 revenue reached US$90.2 million, up 28%.
Cash buys time for clinical trials
Several drug developers used fresh capital or existing reserves to fund their next studies. PYC Therapeutics (ASX:PYC) reported $669 million in cash while advancing four RNA drug programmes. Echo IQ (ASX:EIQ) raised $110 million and secured up to $20 million from Pro Medicus to expand its heart diagnosis software in the US. BlinkLab (ASX:BB1) raised A$17.5 million and received a US patent for its remote testing technology.
Clarity Pharmaceuticals (ASX:CU6) held $178.3 million in cash and signed a US manufacturing deal with Nucleus RadioPharma. Its prostate cancer imaging study found 2.6 times more lesions than standard care. Mesoblast (ASX:MSB) recorded US$115 million in first-year Ryoncil revenue after FDA approval, but its shares fell 7.66% as investors weighed further adult trials and debt repayment.
Clinical news met mixed share-price reactions
Nyrada (ASX:NYR) rose 18.52% after dosing the first patient in its Phase IIa heart attack recovery trial and receiving a US patent allowance. Syntara (ASX:SNT) gained 15.91% after positive FDA feedback on its planned myelofibrosis trial and an $8 million placement.
Not every clinical update brought a higher share price. Alterity Therapeutics (ASX:ATH) received FDA agreement on a single Phase 3 trial for its Alzheimer’s-related drug, yet fell 2.68%. Avecho Biotechnology (ASX:AVE) also fell 9.52% despite approval to continue its insomnia trial without adding patients. These trials still need to produce useful results before they can support wider treatment use.
Commercial growth beyond hospitals
Revenue growth was strongest among businesses already selling products. BLS Pharmaceuticals (ASX:BLS) reported FY26 revenue of $74.98 million, up 156%, and secured a $50 million German supply deal. Biome Australia (ASX:BIO) posted record sales of $23.9 million, up 30%, while Adherium (ASX:ADR) recorded a fourth quarter of record remote monitoring revenue. PainChek (ASX:PCK) lifted implemented annual recurring revenue to $4.46 million as its first two US sites went live.
At the smaller end of the market, ReNerve (ASX:RNV) reported record quarterly sales of $211,000, up 50% from the previous quarter. Tissue Repair (ASX:TRP) moved 15.38% after randomising 100 patients in its US wound trial. By contrast, Argent BioPharma (ASX:RGT) fell 20.00% despite removing US$5.5 million of secured debt through a licensing agreement. The price response shows that balance-sheet relief does not always outweigh concerns about the company’s very small cash balance.
Bottom Line?
The next milestones are scheduled clinical results, regulatory submissions and commercial launches. Actinogen expects topline XanaMIA Alzheimer’s trial results in November 2026. Clinuvel expects vitiligo trial results in December 2026, while Tissue Repair is targeting an FDA 510(k) submission in October 2026. LTR Pharma plans to prepare its FDA submission and launch ROXUS in the US during the second half of 2026.
Questions in the middle?
- Can Xenitra convert the Kangsheng agreement into recurring orders after operational onboarding?
- Will Artrya’s expected US FDA submission and Salix revenue growth reverse the recent share-price fall?
- Can the sector’s larger cash raises produce approval, trial and sales milestones before reserves decline?